How to manage the adverse reactions of gaffetuzumab

Glofitamab (Glofitamab), as a new immunotherapy drug, has significant therapeutic effects in the treatment of non-Hodgkin lymphoma, but like all drugs, patients may still experience certain adverse reactions during treatment. Therefore, timely recognition and management of adverse reactions is key to ensuring smooth treatment.

One of the most common side effects is cytokine release syndrome (CRS). This is a systemic inflammatory response triggered by rapid activation of the immune system that often occurs early in treatment, especially when gaffetuzumab is first used. Symptoms of CRS include fever, chills, low blood pressure, difficulty breathing, nausea, and headache.

For patients who develop CRS, timely management measures are very important, including giving anti-inflammatory drugs (such as steroids) to reduce symptoms, and helping to maintain blood pressure and respiratory function through fluid supplementation, oxygen support, etc. During the treatment process, doctors need to adjust the drug dosage or delay the administration time based on the patient's symptom severity and treatment response to avoid the occurrence of serious adverse reactions.

In addition, gaffetuzumab may also cause other immune system-related side effects, such as allergic reactions, rashes, joint pain, etc. These reactions are usually mild, but in individual patients they may worsen symptoms and even affect quality of life. For patients who experience allergic reactions, the medication should be stopped immediately and emergency treatment should be provided according to the situation. If a severe allergic reaction occurs, further treatment or a change of medication may be needed.

Other common side effects include fatigue, nausea, and decreased appetite. Most of these side effects are transient during treatment and gradually resolve as treatment progresses. However, if symptoms persist or worsen, patients should report it to their doctor promptly so that the treatment plan can be adjusted in a timely manner.

Reference materials:https://www.drugs.com/glofitamab.html